Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flows from operating activities
Net loss	$ (50,764)	$ (69,421)
Adjustments to reconcile net loss to cash used in operating activities
Depreciation	1,046	751
Amortization of right-of-use assets	867	809
Stock-based compensation expense	8,615	8,438
Provision for inventory	560	0
Non cash interest expense	454	292
Amortization (accretion) of premium (discount) on marketable securities	401	(52)
Loss on disposal of fixed assets	0	262
Amortization of debt discount and debt issuance costs	5,028	4,577
Premium paid on securities purchased	3	(17)
Changes in operating assets and liabilities:
Accounts receivable	(5,072)	15,591
Inventory	2,533	(2,502)
Prepaid expenses and other current assets	(362)	328
Accounts payable	(1,286)	(7,540)
Accrued expenses and other current liabilities	1,469	(4,375)
Deferred revenue	0	5,000
Lease liabilities	(728)	(748)
Net cash used in operating activities	(37,236)	(48,607)
Cash flows from investing activities
Purchases of property and equipment	(1,265)	(5,538)
Purchases of marketable securities	(2,000)	(12,490)
Sale and redemption of marketable securities	45,561	49,398
Net cash provided by investing activities	42,296	31,370
Cash flows from financing activities
Proceeds from borrowings under term loan	0	15,000
Proceeds from revolving line of credit	0	20,000
Repayments of revolving line of credit	0	(15,000)
Proceeds from the offering of common stock	0	97,289
Proceeds from issuance of common stock (net of issuance costs)	1,700	0
Payments of public offering costs	(125)	(107)
Payments on notes payable	(7,639)	0
Proceeds from the exercise of stock options (net of shares withheld for taxes)	8	10
Proceeds from employee stock purchase plan	921	891
Net cash (used in) provided by financing activities	(5,135)	118,083
Net (decrease) increase in cash and cash equivalents	(75)	100,846
Cash and cash equivalents at beginning of period	107,704	82,253
Cash and cash equivalents at end of period	107,629	183,099
Non-cash operating, investing and financing activities
Right-of-use asset obtained in exchange for operating lease obligation	433	0
Purchases of property and equipment in accounts payable and accrued expenses	264	2,126
Public offering costs in accounts payable and accrued expenses	0	418
Supplemental disclosures of cash flow information
Cash paid for interest	$ 5,259	$ 5,048

Flexion Therapeutics Inc 10-Q